Collegium acquires Nucynta patents from Grünenthal under settlement
COLL•Collegium Pharmaceutical paid Grünenthal $17 million under an October 15, 2026, settlement resolving all disputes, including Nucynta ER patent litigation. Grünenthal transferred certain Nucynta patents, and the settlement ended the license and all remaining royalty obligations.
1. Settlement terms
Collegium Pharmaceutical paid Grünenthal $17 million under an October 15, 2026, settlement resolving all disputes, including Nucynta ER patent litigation. Grünenthal transferred certain Nucynta patents to Collegium and filed a motion to dismiss the litigation; the settlement also terminated the Grünenthal license and eliminated all remaining royalty obligations.
